FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:433-434 February 6, 1997 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Patients with venous thromboembolic disease require treatment to stop the thrombotic process. The importance of immediate therapy with parenteral anticoagulants or thrombolytic agents (or both) is unquestioned.^1,2 Furthermore, several well-designed clinical trials have demonstrated that oral anticoagulant therapy with warfarin derivatives prevents the development of recurrent thromboembolic disease,^3,4,5,6 whereas inadequate anticoagulant therapy carries a risk of recurrent thromboembolism that can be as high as 25 percent.⁵ These studies also show that prolonged anticoagulant therapy is associated with an increased risk of bleeding.^3,4,5,6 This risk can be lessened, but not eliminated, by appropriate monitoring of warfarin therapy.^7,8 Moreover, with treatment, the . . . [Full Text of this Article]

References

Related Letters:

Venous Thromboembolism
Block J. A., White T. M., Fetrow C.W., Schulman S., The Duration of Anticoagulation Trial Study Group , Diuguid D. L.
Extract | Full Text  
N Engl J Med 1997; 337:51-53, Jul 3, 1997. Correspondence

This article has been cited by other articles:

• Stoschitzky, K., Stark, G., Dacar, D., van der Wouw, P. A., Bax, M. (1997). Massive Pulmonary Embolism. NEJM 337: 1561-1562 [Full Text]  
• Block, J. A., White, T. M., Fetrow, C.W., Schulman, S., The Duration of Anticoagulation Trial Study Group, , Diuguid, D. L. (1997). Venous Thromboembolism. NEJM 337: 51-53 [Full Text]